US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.68 against a street estimate of 0.66 — a beat of 3.0%.
Analysts rate LeMaitre Vascular Inc a buy (5 buy, 6 hold, 0 sell out of 11) with an average price target of $118.75.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.76% |
| Conestoga Capital Advisors, LLC | 5.98% |
| First Trust Advisors L.P. | 4.37% |
| Congress Asset Management Company, LLP | 4.22% |
| Vanguard Capital Management, LLC | 3.99% |
| Copeland Capital Management, LLC | 3.81% |
| State Street Corp | 3.75% |
| Geneva Capital Management | 3.30% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-05 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-14 |
| Board / officer change · Q2 2026 | 2026-04-14 |
| Annual report FY2025 | 2026-02-26 |
| Results announced · Q1 2026 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for LeMaitre Vascular Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.